Clinical trials: Heart Failure with Reduced Ejection Fraction HFrEF
Heart Failure With Reduced Ejection Fraction
Dietary Intervention and Physical Activity in Patients With Heart Failure and Reduced Ejection Fraction
Heart failure with reduced ejection fraction (HFrEF) is frequently associated with abnormalities in body composition, including reduced skeletal muscle mass and sarcopenia, which are independent predictors of reduced exercise…
- Trial name
- NCT07595809
- Testing
- Resistance Exercise, Dietary Intervention
- Where
- Poland
- Volunteers
- 100 people
- Sponsor
- Medical University of Silesia
Heart Failure, Heart Failure With Reduced Ejection Fraction
The Effect of Obesity and Weight Loss in Heart Failure With Reduced Ejection Fraction.
This study looks at the effects of weight loss in people who have heart failure with reduced ejection fraction (HFpEF) and are overweight or obese.
- Conditions
- Heart Failure, Heart Failure With Reduced Ejection Fraction, Obesity, Overweight
- Trial name
- SLEnDR (NCT05942287)
- Testing
- Diet intervention
- Where
- 2 sites in Jersey, United Kingdom
- Volunteers
- 110 people
- Sponsor
- University of Oxford
Ventricular Ejection Fraction, LVF
AI-Enabled Direct-from-ECG Ejection Fraction (EF) Severity Assessment Using COR ECG Wearable Monitor
This prospective, multicenter, cluster-randomized controlled study aims to evaluate the accuracy of an investigational artificial intelligence (AI) Software as a Medical Device (SaMD) designed to compute ejection fraction (EF)…
- Conditions
- Ventricular Ejection Fraction, LVF, LV Dysfunction, Atrial Enlargement
- Trial name
- EFACT (NCT06699056)
- Testing
- 15-minutes of sitting during COR ECG Acquistion
- Where
- 8 sites in United States
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Peerbridge Health, Inc
HFrEF - Heart Failure With Reduced Ejection Fraction
Vsling™ III: Clinical Evaluation of the Vsling™ Device for Ventricular Repair in Patients With Heart Failure
Prospective, multi-center, open-label clinical study of the feasibility and initial safety and performance of the Vsling™ in patients with heart failure (HF) with evidence of reduced left ventricular ejection fraction, associated…
- Trial name
- Vsling III (NCT06002386)
- Testing
- Vsling
- Where
- Poland
- Volunteers
- 10 people
- Sponsor
- Cardiac Success
Heart Failure With Reduced Ejection Fraction, Coronary Artery Disease
Assessment of Biomarkers in Patients With Decompensated Heart Failure and Underlying Coronary Artery Disease
Assessment of Biomarkers in Patients with Decompensated Heart Failure and Underlying Coronary Artery Disease
- Trial name
- NCT03551756
- Testing
- Biomarker Assessment
- Where
- 3 sites in United States
- Volunteers
- 94 people, healthy volunteers welcome
- Sponsor
- CirQuest Labs, LLC
Heart Failure With Reduced Ejection Fraction
HFrEF Polypill in Sri Lanka RCT
The aim of this study is to evaluate, in adults with HFrEF in Sri Lanka, the effects of an HFrEF polypill implementation strategy on the composite rate of cardiovascular disease mortality and recurrent heart failure…
- Trial name
- NCT07569640
- Testing
- Usual Care, HFrEF Polypill
- Where
- 12 sites in Sri Lanka
- Volunteers
- 1,672 people
- Sponsor
- Washington University School of Medicine
Left Ventricular Diastolic Function
Impact of Sacubitril/Valsartan on LV Diastolic Function in HFrEF
This prospective cohort study evaluates the effects of six months of sacubitril/valsartan (ARNI) therapy on left ventricular diastolic function in patients with heart failure with reduced ejection fraction (HFrEF) using…
- Trial name
- NCT07157527
- Volunteers
- 70 people
- Sponsor
- Assiut University
Hyperkalaemia, Heart Failure With Reduced Ejection Fraction
Study to Assess Efficacy and Safety of SZC for the Management of High Potassium in Patients With Symptomatic HFrEF Receiving Spironolactone
The main objective of this study is to evaluate the efficacy of SZC as compared with placebo in keeping potassium levels within the normal range (3.5-5.0 mEq/L) while on spironolactone ≥25 mg daily without assistance of rescue…
- Trial name
- REALIZE-K (NCT04676646)
- Testing
- Sodium zirconium cyclosilicate, Spironolactone
- Where
- 89 sites in United States, Brazil and 6 more
- Volunteers
- 366 people
- Sponsor
- AstraZeneca
Arterial Hypertension, Atherosclerosis Occlusive Disease
Gut Microbiota in Chronic Noncommunicable Diseases
It is an observational study in patients with chronic noncommunicable diseases (i.e. cardiovascular diseases, diabetes mellitus, non-alcoholic fatty liver disease, chronic obstructive pulmonary disease and asthma ) and control…
- Conditions
- Arterial Hypertension, Atherosclerosis Occlusive Disease, Heart Failure With Preserved Ejection Fraction, Heart Failure With Reduced Ejection Fraction
- Trial name
- NCT04820556
- Where
- 2 sites in Russia
- Volunteers
- 1,084 people
- Sponsor
- National Medical Research Center for Therapy and Preventive Medicine
Sodium-GLucose coTransporter-2 Inhibitors, Heart Failure With Reduced Ejection Fraction
Deformation Imaging by Strain in Chronic Heart Failure Over Gliflozins: an Echocardiographic Register on Sodium-GLucose coTransporter-2 Inhibitors
It is an observational, cohort, prospective, multicentre, Italian, non-profit study, with the aim of evaluating the modification of conventional and advanced echocardiographic parameters, focusing on speckle tracking and…
- Trial name
- DISCOVERSGLT2i (NCT05344963)
- Testing
- Sodium-GLucose coTransporter-2 inhibitors
- Where
- Italy
- Volunteers
- 503 people
- Sponsor
- Matteo Cameli
Heart Failure With Reduced Ejection Fraction
A Study to Assess the Effect of Danicamtiv on the Drug Levels of Midazolam in Participants With Stable Heart Failure
The purpose of this study is assess the effect of danicamtiv, as an inducer on the drug levels of midazolam in participants with heart failure with reduced ejection fraction (HFrEF).
- Trial name
- NCT05952089
- Testing
- Danicamtiv, Midazolam
- Where
- 5 sites in United States
- Volunteers
- 13 people
- Sponsor
- Bristol-Myers Squibb
Heart Failure With Reduced Ejection Fraction, Congestion
ERTU-SODIUM: Study on the Effects of Ertugliflozin on Sodium Storage, Interstitial Volume, and Plasma Volume in HFrEF
The overall hypothesis is that treatment with the SGLT2 inhibitor Ertugliflozin induces a differential regulation in interstitial fluid vs plasma volume, with more reduction of the volume from the interstitial fluid than from the…
- Trial name
- ERTU-SODIUM (NCT05152940)
- Testing
- Ertugliflozin
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Heart Failure, Sarcopenia
The Sarcopenia Study
The goal of this cross-sectional study is to investigate the prevalence of sarcopenia in patients with Heart Failure. The main question it aims to answer is: Whether there is a difference in the prevalence of sarcopenia across…
- Conditions
- Heart Failure, Sarcopenia, Heart Failure With Reduced Ejection Fraction, Heart Failure With Preserved Ejection Fraction
- Trial name
- NCT05888688
- Where
- United Kingdom
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- University of Leicester
Heart Failure With Reduced Ejection Fraction
Phase Ib/IIa Trial With AC01 in Patients With HFrEF
This is a randomized, double-blind, placebo-controlled two-part study with a multiple escalating dose phase followed by a cohort expansion phase to assess safety, tolerability, pharmacokinetics and pharmacodynamics of AC01 in…
- Trial name
- GOAL-HF1 (NCT05642507)
- Testing
- AC01
- Where
- 14 sites in Italy, Netherlands and 2 more
- Volunteers
- 58 people
- Sponsor
- AnaCardio AB
Heart Failure, Cardiomyopathy, Dilated
Ventricular Sling for Heart Failure With Reduced Ejection Fraction
The purpose of this research is to investigate the effect of using this surgical technique in conjunction with bypass surgery to improve heart function and size, as well as decrease the possibility of future mitral valve surgery.
- Trial name
- NCT04475315
- Testing
- Papillary Muscle Sling, CABG surgery
- Sponsor
- University of Miami
Heart Failure With Reduced Ejection Fraction
Email Nudges to Improve GDMT (MRA) Adherence in Heart Failure
The Email Nudges to Improve GDMT (MRA) Adherence in Heart Failure (ENIGMA-HF) study is a pragmatic parallel-arm randomized control trial of a quality improvement (QI) intervention involving email nudges to cardiology clinic…
- Trial name
- ENIGMA-HF (NCT05806970)
- Testing
- Email Nudge
- Where
- United States
- Sponsor
- University of California, Los Angeles
Type2 Diabetes, Heart Failure With Reduced Ejection Fraction
The Effects of SGLTi on Diabetic Cardiomyopathy
Diabetic cardiomyopathy is associated with significant morbidity and mortality. It is considered as a cardiac muscle disorder secondary to diabetes mellitus (DM).
- Trial name
- SGLTi (NCT04200586)
- Testing
- Dapagliflozin
- Where
- Hong Kong
- Volunteers
- 30 people
- Sponsor
- The University of Hong Kong
Heart Failure With Reduced Ejection Fraction
Comparison of Effects of Atorvastatin Versus Rosuvastatin on Cardiac Function in Heart Failure Patients
Statins have a protective effect in patients with established heart failure because of their lipid-lowering and pleiotropic effects.
- Trial name
- ASTRO-CHF (NCT05072054)
- Testing
- Atorvastatin Oral Tablet, Rosuvastatin Oral Tablet
- Where
- India
- Volunteers
- 80 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Chronic Heart Failure
Intestinal Microbiota Transplantation in Patients With Chronic Heart Failure
The purpose of this study is to determine whether people with CHF, who often have different gut bacteria from healthy, would benefit from replacing their gut bacteria with healthy donor bacteria (also known as Intestinal…
- Trial name
- IMT (NCT07490054)
- Testing
- MTP-101-C encapsulated Microbiota, Vancomycin, Neomycin
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Melana Yuzefpolskaya, MD
Heart Failure, Chronic Heart Failure With Reduced Ejection Fraction
A Study of Vericiguat in Participants With Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-001)
This is a randomized, placebo-controlled, parallel-group, multi-center, double-blind, event driven study of vericiguat (MK-1242) in participants with heart failure with reduced ejection fraction (HFrEF).
- Trial name
- VICTORIA (NCT02861534)
- Testing
- Vericiguat
- Volunteers
- 5,050 people
- Sponsor
- Merck Sharp & Dohme LLC